We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy Signs FDA Consent Decree, Diverts $500 Million for Fraud Probe
Ranbaxy Signs FDA Consent Decree, Diverts $500 Million for Fraud Probe
January 4, 2012
Indian generic-drug giant Ranbaxy Laboratories entered into a consent decree with the FDA to resolve lingering manufacturing problems at two plants.